Molbank
(Nov 2022)
Dichloro[<i>N</i>-[(η<sup>6</sup>-phenyl)methyl]-4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8tetrahydronaphthalen-2-yl)vinyl)benzamide](1,3,5-triaza-7-phosphatricyclo [3.3.1.1<sup>3,7</sup>]decane-κP<sup>7</sup>)ruthenium
Ilya A. Shutkov,
Dmitrii M. Mazur,
Nataliya E. Borisova,
Elena R. Milaeva,
Alexey A. Nazarov
Affiliations
Ilya A. Shutkov
Department of Chemistry, M. V. Lomonosov Moscow State University, Leninskie Gory 1/3, 119991 Moscow, Russia
Dmitrii M. Mazur
Department of Chemistry, M. V. Lomonosov Moscow State University, Leninskie Gory 1/3, 119991 Moscow, Russia
Nataliya E. Borisova
Department of Chemistry, M. V. Lomonosov Moscow State University, Leninskie Gory 1/3, 119991 Moscow, Russia
Elena R. Milaeva
Department of Chemistry, M. V. Lomonosov Moscow State University, Leninskie Gory 1/3, 119991 Moscow, Russia
Alexey A. Nazarov
Department of Chemistry, M. V. Lomonosov Moscow State University, Leninskie Gory 1/3, 119991 Moscow, Russia
DOI
https://doi.org/10.3390/m1506
Journal volume & issue
Vol. 2022,
no. 4
Abstract
Read online
Bexarotene-tethered RuII(arene) compounds with 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane (PTA) were prepared as an analog of RAPTA antitumor complexes in order to evaluate their in vitro antiproliferative activity against human cancer cell lines.
Keywords
WeChat QR code
Close
